Yazar "Doğu, Mehmet Hilmi" için listeleme
-
Acute lymphoblastic leukemia in routine practice: A Turkish multicenter study
Çiftçiler, Rafiye; Sevindik, Ömür Gökmen; Tekgündüz, Ali İrfan Emre; Erkurt, Mehmet Ali; Vural, Filiz; Turgut, Burhan; Kaynar, Leylagül; Payzın, Bahriye; Doğu, Mehmet Hilmi; Karakuş, Volkan; Altuntaş, Fevzi; Büyükaşık, Yahya; Demirkan, Fatih (Turkish Society of Hematology, 2019)Objective: Significant developments occurred in the clinical management of acute lymphoblastic leukemia (ALL) in adults in recent decades. However, treatment results are still not satisfactory, especially in routine practice. ... -
Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: A multicenter experience
Gören Şahin, Deniz; Akay, Olga Meltem; Keklik, Muzaffer; Okan, Vahap; Karakuş, Abdullah; Demir, Cengiz; Erkurt, Mehmet Ali; İlkkılıç, Kadir; Yıldırım, Rahşan; Akgün Çağlıyan, Gülsüm; Aksu, Salih; Doğu, Mehmet Hilmi; Dal, Mehmet Sinan; Karakuş, Volkan; Gemici, Aliihsan; Terzi, Hatice; Kelkitli, Engin; Şıvgın, Serdar; Ünal, Ali; Yılmaz, Mehmet; Ayyıldız, Orhan; Korkmaz, Serdal; Eser, Bülent; Altuntaş, Fevzi (Springer, 2021)The aim of this study is to collect paroxysmal nocturnal hemoglobinuria (PNH) patient data from hematology centers all over Turkey in order to identify clinical features and management of PNH patients. Patients with PNH ... -
Gilteritinib (XOSPATA (R)) in Turkey: Early access program results
Doğu, Mehmet Hilmi; Tekgündüz, Ali İrfan Emre; Deveci, Burak; Korkmaz, Gülten; Cömert, Melda; Sevindik, Ömür Gökmen; Yokuş, Osman; Serin, İstemi (Mattioli 1885, 2023)Background And Objectives: Gilteritinib (XOSPATA (R), Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ... -
Nivolumab for relapsed or refractory hodgkin lymphoma experience in Turkey
Ferhanoğlu, Burhan; Beköz, Hüseyin Saffet; Karadurmuş, Nuri; Paydaş, Semra; Gülbaş, Zafer; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Tekgündüz, Emre; Kaya, Ali Hakan; Taştemir, N.; Arat, Mutlu; Pepedil Tanrıkulu, Funda; Özkocaman, Vildan; Abalı, Hüseyin; Turgut, Mehmet; Kaynar, Leylagül; Karadoğan, İhsan; Özbalak, Murat; Özcan, Muhit; Doğu, Mehmet Hilmi; Kabukçu Hacıoğlu, Sibel; Yıldırım, Rahsan; Barışta, İbrahim; Demirkaya, Metin; Köseoğlu, Fatoş Dilan; Yüksel, Meltem Kurt; Sönmez, Mehmet; Toprak, Selami Koçak (Ferrata Storti Foundation, 2017)… -
Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
Beköz, Hüseyin Saffet; Karadurmuş, Nuri; Paydaş, Semra; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Sönmez, Mehmet Giray; Gülbaş, Zafer; Tekgündüz, Emre; Kaya, Ali Hakan; Özbalak, Murat; Taştemir, N; Kaynar, Leylagül; Yildirim Rahşan; Karadoğan, İhsan; Arat Ersöz, Mutlu; Pepedil Tanrıkulu, Funda; Özkocaman, Vildan; Abali, Hüseyin; Turgut, Mehmet; Kurt Yüksel, M; Özcan, Muhit; Doğu, Mehmet Hilmi; Kabukçu Hacıoğlu, Sibel; Barişta, İbrahim; Demirkaya, Metin; Köseoğlu, Fatoş Dilan; Toprak, Selami Koçak; Yilmaz, Mehmet Birhan; Demirkürek, Hüseyin; Demirkol, Mehmet Onur; Ferhanoğlu, Burhan (Oxford University Press, 2017)Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, ... -
Quality of life assessment with EORTC QLQ in patients with hodgkin lymphoma: Multicenter study
Gemici, Aliihsan; Serin, İstemi; Erol, Vedat Buğra; Doğu, Mehmet Hilmi; İnce, İdris; Eren, Rafet; Tekinalp, Atakan; Karakuş, Volkan; Sevindik, Ömür Gökmen (Ankara Hematology Oncology Association, 2022)Aim: The aim of our study is to obtain data on the quality of life (QoL) in Hodgkin lymphoma (HL) patients in a representative sample of the general population of Turkey with the help of the EORTC QLQ-C30 and QLQ-HL27 ... -
Quality of life assessment with EORTC QLQ in patients with multiple myeloma: Multicenter study
Gemici, Aliihsan; Serin, İstemi; Erol, Vedat Buğra; Doğu, Mehmet Hilmi; İnce, İdris; Eren, Rafet; Tekinalp, Atakan; Karakuş, Volkan; Koç Erol, İklil Nur; Arslan, Zeynep Ece; Tay, Zekiye Nur; Tuncer, Elif Nur; Sevindik, Ömür Gökmen (Galenos Publishing House, 2022)Objective: Both the length of the treatment period and the diversity of the agents used in the treatment significantly affect the quality of life (QoL) of the patients with multiple myeloma (MM). With the aid of the EORTC ... -
A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia
Gemici, Aliihsan; Özkalemkaş, Fahir; Doğu, Mehmet Hilmi; Tekinalp, Atakan; Alacacıoğlu, İnci; Güney, Tekin; İnce, İdris; Gedük, Ayfer; Akgün Çağlıyan, Gülsüm; Maral, Senem; Serin, İstemi; Gündüz, Eren; Karakuş, Volkan; Beköz, Hüseyin Saffet; Eren, Rafet; Pınar, İbrahim Ethem; Güneş, Ahmet Kürşad; Sargın, Fatma Deniz; Sevindik, Ömür Gökmen (CIG Media Group, 2021)Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients ... -
Relaps/refrakter lenfoma (mantle hücreli lenfoma hariç) hastalarında lenalidomid bazlı tedavi sonuçları: Çok merkezli sonuçlar
Amaç: Lenfomalar, çoğunlukla B hücre kökenli heterojen bir hastalık grubunu temsil eder. Lenalidomid, kemo-immünoterapötik ajanlara talidomidin yapısal bir analoğu olarak dahil edilmiştir. Bu çalışmada amaç, mantle hücreli ... -
Turkish acute lymphoblastic leukemia registry, retrospective phase data
Demirkan, Fatih; Çiftçiler, Rafiye; Sevindik, Ömür Gökmen; Tekgündüz, Emre; Erkurt, Mehmet Ali; Vural, Filiz; Turgut, Burhan; Kaynar, Leylagül; Payzin, Kadriye Bahriye; Doğu, Mehmet Hilmi; Karakuş, Volkan; Altuntaş, Fevzi; Büyükaşık, Yahya (The American Society of Hematology, 2019)Background and Aim: Significant developments have occurred in clinical management of acute lymphoblastic leukemia (ALL) in adults over recent decades. However, treatment results are still not satisfactory especially in ...